Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar
- PMID: 28823072
- DOI: 10.1007/s11096-017-0526-3
Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar
Abstract
Background Digoxin is a cardiac glycoside that is recommended by clinical practice guidelines to be used in patients with heart failure with reduced ejection fraction (HFrEF) who still have persistent symptoms despite optimal medical therapy. However, this recommendation is based on limited and old trial data. Moreover, pharmacoepidemiologic studies are important in determining the prevalence of digoxin use and factors influencing this. Objective This study aimed to determine the prevalence and the predictors of digoxin utilization among patients with HFrEF with or without atrial fibrillation (AF) in Qatar. Setting Heart Hospital, a specialized tertiary care center in Qatar. Methods A retrospective observational study was conducted using Cerner electronic medical records. Subjects included 736 patients admitted between January 1, 2013 and December 31, 2014 with the diagnosis of HFrEF with or without AF. Two groups of patients were studied: digoxin users and digoxin non-users at index hospitalization until discharge. Univariate and multivariate binary logistic regression analyses were conducted to determine the predictors of digoxin prescription. Data analyses were performed using IBM SPSS® version 23.0. Main outcome measures Prevalence and predictors of digoxin prescriptions among HFrEF patients measured in percentages and odds rations, respectively. Results A total of 736 patients who met the inclusion criteria were analyzed for digoxin prevalence, including 80 patients (11%) who were newly prescribed digoxin during the index hospitalization. After adjusting for patient demographics and clinical characteristics, the use of thiazide diuretics (aOR = 10.14, CI 2.31-44.6, p value = 0.002), concurrent AF (aOR = 8.2, CI 3.11-21.7, p < 0.001), and an ejection fraction (EF) <25% (aOR = 3.2, CI 1.5-6.8, p value = 0.002) significantly predicted digoxin prescriptions among patients with HFrEF. Conclusion The rate of digoxin prescription among patients with HFrEF in Qatar is relatively low. The strongest predictors of digoxin use in HFrEF patients were the concomitant use of thiazide diuretics and concurrent diagnosis of AF. The findings may potentially serve as useful guides for the rational utilization of digoxin in patients with HFrEF.
Keywords: Atrial fibrillation; Digoxin; Heart failure; Predictors; Prescription; Qatar; Retrospective study.
Similar articles
-
Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry.JACC Heart Fail. 2016 May;4(5):348-56. doi: 10.1016/j.jchf.2015.12.003. Epub 2016 Feb 10. JACC Heart Fail. 2016. PMID: 26874392
-
Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.Int J Clin Pharm. 2016 Apr;38(2):353-61. doi: 10.1007/s11096-016-0250-4. Epub 2016 Jan 9. Int J Clin Pharm. 2016. PMID: 26749343
-
Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study.Eur Heart J. 2019 Jul 1;40(26):2110-2117. doi: 10.1093/eurheartj/ehz233. Eur Heart J. 2019. PMID: 31280320
-
Clinical Use of Digitalis: A State of the Art Review.Am J Cardiovasc Drugs. 2018 Dec;18(6):427-440. doi: 10.1007/s40256-018-0292-1. Am J Cardiovasc Drugs. 2018. PMID: 30066080
-
Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.Circulation. 2017 Apr 18;135(16):1547-1563. doi: 10.1161/CIRCULATIONAHA.116.026054. Circulation. 2017. PMID: 28416525 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous